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Abstract
Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for
example, dopaminergic neural cells for Parkinson’s Disease to pancreatic islets to relieve diabetic patients of
their daily insulin injections. While an embryo has the innate capacity to develop fully functional diﬀer-
entiated tissues; biologists are ﬁnding that it is much more complex to derive singular, pure populations of
primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in
developing the technologies to expand and diﬀerentiate these cells is required in the next decade to move
this promise into reality. In this review we document the current standard assays for characterising human
ESC (hESC), the status of ‘deﬁned’ feeder-free culture conditions for undiﬀerentiated hESC growth,
examine the quality controls that will be required to be established for monitoring their growth, review
current methods for expansion and diﬀerentiation, and speculate on the possible routes of scaling up the
diﬀerentiation of hESC to therapeutic quantities.
Introduction
Embryonic stem cells are pluripotent, capable of
diﬀerentiation as well as unlimited self-renewal
which theoretically make them ideal for replace-
ment, repair or regeneration of tissues and organs.
This review covers the current state of the known
art and developments in the technologies needed
for identifying and manipulating these versatile
cells towards their full potentials.
Human embryonic stem cells
What is a human embryonic stem cell?
There are several important features that deﬁne
an embryonic stem cell (ESC); these are listed in
Table 1 (Pera et al. 2000). Typically the charac-
teristic transcription factors include Oct4, Nanog
and Sox2; human telomerase and alkaline phos-
phatase are also highly expressed, along with a
panel of cell surface markers including SSEA-3
and SSEA-4, which detect the globoseries glycoli-
pids, and Tra-1-60, Tra-1–81 and GCTM-2 which
detect proteoglycans such as keratan sulphate. In
addition, when human ESC (hESC) are cultured in
suspension, they form embryoid body structures
which, when left to diﬀerentiate without manipu-
lation, can give rise to a variety of phenotypes.
These same cells, when injected into severe
combined immuno-deﬁcient (SCID) mice, form
teratomas which consist of tissues from all three of
the germ layers, ecto-, meso- and endoderm. While
surface antigen markers have been used for the
identiﬁcation of hESC in various labs, there has
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range of hESC lines in diﬀerent labs for the pro-
portion of expression of these markers. It is pos-
sible that the diﬀerent hESC isolates, method of
derivation and culture conditions may cause het-
erogeneity of these markers. Thus the Interna-
tional Stem Cell Initiative led by Prof. Peter
Andrews was organized to characterize 77 hESC
cell lines from 15 nations with the goal of deter-
mining if there is any variability in antigen marker
levels, as well as gene expression upon diﬀerenti-
ation, between these cell lines (Andrews et al.
2005). This eﬀort is important as no other stem cell
community has planned such an ambitious
undertaking to date.
Deﬁning culture conditions for hESC
In any attempt to scale up hESC for the purpose of
clinical studies, a deﬁned culture system will be a
ﬁrst irreducible goal (Bongso et al. 2005). Until
recently, hESC have been cultured on a variety of
feeder cell lines or the conditioned media (CM)
made from these cells (Thomson et al. 1998; Choo
et al. 2004). However, in the ﬁrst half of this year,
we have made signiﬁcant progress in understand-
ing how to maintain hESC in feeder-free envi-
ronments, by supplementing with either basic
ﬁbroblastic growth factor (FGF-2) alone (Li et al.
2005; Xu et al. 2005a) or in combination with
either noggin (Wang et al. 2005; Xu et al. 2005b)
or with activin A (Beattie et al. 2005). These con-
ditions summarized in Table 2, lead one to spec-
ulate that hESC are much more complex and
versatile than mouse ESC (mESC) in the ways they
regulate self-renewal and prevent diﬀerentiation.
In essence, besides the traditional feeder cultures
or CM from feeders; one camp has identiﬁed
FGF-2 signalling to be critically important in self-
renewal (see the ﬁrst four references in Table 2),
while another group postulates that the trans-
forming growth factor beta (TGFb) signalling
pathways are necessary for preventing diﬀerentia-
tion by default, (see last four references in
Table 2). These latest reports seem to suggest that
hESC requires FGF-2 for self-renewal while at the
same time the blockage of BMP signalling is nee-
ded in retaining their phenotype. This is a dis-
tinctly diﬀerent paradigm from mESC
pluripotency which is solely dependent on
leukaemia inhibitory factor (LIF) which activates
Table 1. Characteristic markers of hESCs.
Transcription factors Oct4, Nanog, Sox2
Surface markers Stage speciﬁc embryonic antigens SSEA-3/4, Tumour
related antigens Tra-1-60/1-81, GCTM-2
Other markers Human telomerase enzyme, Alkaline phosphatase
In vitro diﬀerentiation Neural lineage, Haematopoietic lineage, Cardiac lineage
In vivo diﬀerentiation (SCID assay) Ectoderm, Mesoderm, Endoderm
Karyotype 23 pairs of chromosomes
Doubling time Typically 30±2 h (Ranges from 24 to 48 h)
Table 2. Growth factors and putative pathways in maintaining hESC pluripotency.
Culture conditions of hESC Putative pathways involved in pluripotency Reference
FGF-2 alone, hESC seeded at high densities FGF-2 signalling Draper et al. (2004a)
FGF-2 alone at high concentrations (or with
Flt ligand)
FGF-2 signalling Xu et al. (2005a)
FGF-2 and noggin FGF-2 signalling, suppression
of BMP signalling
Xu et al. (2005b)
FGF-2 alone at high concentrations FGF-2 signalling Li et al. (2005)
TGFb and FGF-2 TGFb/FGF-2 signalling? Amit et al. (2004)
Activin A, and FGF-2 Activin A signalling, SMAD2/3 activation Besser (2004)
Activin A, nicotinamide and keratinocyte
growth factor
TGFb/Activin A signalling Beattie et al. (2005)
Activin A or GSK3b inhibitor TGFb/Activin A signalling,
SMAD2/3 activation
James et al. (2005)
182the Jak/Stat pathway, while this pathway fails to
maintain self-renewal in hESC (Daheron et al.
2004).
It appears that the bone morphogenetic pro-
teins, BMP-2 and -4, which may be present in
serum or serum replacer, and possibly released
from hESC themselves (Wang et al. 2005; Xu et al.
2005b), may initiate diﬀerentiation by binding to a
pair of BMPR I and BMPR II complexes present
on animal cells, so activating the Smad 1/5/8
pathway (Balemans and Van Hul 2002; Nohe et al.
2004). However, the activity of BMP-4 can be
attenuated by adding high concentrations of
noggin, which sequesters BMP-4, as several groups
have demonstrated (Pera et al. 2004; Gerrard et al.
2005; Wang et al. 2005; Xu et al. 2005b). Noggin
at high concentrations antagonises BMP by
mimicking the BMPR I receptor and binding
tightly to it, as shown in recent crytallographic
studies (Groppe et al. 2002).
Complementary to this, other groups have
shown that activin A supplemented to the media
can also exert the same eﬀect as CM from feeders
(Besser 2004; Beattie et al. 2005; James et al.
2005). Activin A, which belongs to the TGFb
family, also acts through the promiscuous BMPR
I receptor to form a heterodimer with the BMPR
II receptor, causing the downstream phosphory-
lation of Smads 2/3/4 (Dale and Jones 1999; Besser
2004). This has been shown to activate the inhib-
itors of Nodal signalling, Lefty A & B known to be
necessary for maintaining pluripotency (Besser
2004). Thus it is possible that the addition of
activin A competes for the BMPR I and II recep-
tors, which would otherwise bind to BMP-4
causing diﬀerentiation. Activation of one set of
these heterodimeric receptors lead to self-renewal
while the other causes diﬀerentiation. In addition,
the binding of Activin A to the BMPR I and II
receptors leads to Smad 6 and 7 activation, which
inhibits the functions of Smads 1/5/8 (Balemans
and Van Hul 2002). A hypothetical model of stem
cell maintenance summarising the action of these
diﬀerent factors is depicted in Figure 1.
A proteomics approach has been taken by a
team in Australia in order to decipher the identity
of the growth factors in CM and they have iden-
tiﬁed gremlin, which like noggin is a BMP antag-
onist (Prowse et al. 2005). To date however, there
has been no published report of TGFb or activin
Figure 1. A hypothetical model of the action of diﬀerent ligands in maintaining hESC pluripotency. BMP4 which is present in serum
and produced by hESC binds to BMPR I and II receptors to activate Smad 1/5/8 leading to diﬀerentiation. Noggin produced by
feeders can sequester BMP preventing its action. Alternatively Activin A, which belongs to the BMP family can compete for the BMPR
I and II receptors to activate Smad 2/3/4 leading to self-renewal and block the actions of Smad 1/5/8 via Smad 6/7. FGF-2 is postulated
to bind to FGFR1 receptors and activate the Akt/PI3K pathway which is required for self-renewal.
183being found in CM or feeders. Our own structural
studies of CM have identiﬁed several growth fac-
tors, but none belong to the TGFb family
(unpublished data).
A caution about the use of noggin in culture is
that it appears to predispose hESC to diﬀerentiate
towards the neural lineage (Pera et al. 2004;
Gerrard et al. 2005). Thus further investigations
need to be carried out to determine if these factors
can truly maintain a pluripotent phenotype in
long-term cultures. It would also be interesting to
determine which of the BMPR I and BMPR II
receptors on hESC bind to either BMP or activin,
as there are several receptors within each class,
each of which bind with diﬀerent speciﬁcity and
aﬃnity to these ligands. Furthermore, the Smads
activated by these receptor combinations and their
subsequent control of transcription remains to be
understood.
FGFs are an essential component in the
media used for hESC cultures and insights have
come from two recent studies as to how FGF-2
might act on hESC. hESC express all four
FGF receptors, in the following order of abun-
dance: FGFR1>FGFR3>FGFR4>FGFR2
(Dvorak et al. 2005). Phosphorylation of mitogen-
activated protein kinase (MEK1/2) and its sub-
strate ERK1/2 were observed in the presence of
FGF-2. Interestingly, hESC also produced high
molecular weight forms of endogenous FGF-2,
which was speculated to play a role in autocrine
signalling. Another group has apparently shown
that the phosphatidylinositol 3-kinase (PI3K) Akt/
PKB signalling pathway is activated in the pres-
ence of FGF-2 and inhibition of this pathway
leads to the diﬀerentiation of hESC (Kim et al.
2005). Less is known about how the FGF recep-
tors activate downstream signalling pathways in
hESC. Thus it appears that hESC are both very
versatile and pliant in their response to a range of
growth factors and that a ﬁne balance is required
for maintaining them in an undiﬀerentiated state
for long periods of culture.
A ﬁnal comment concerning the current deﬁned
media conditions; it is preferable to eventually
remove the serum replacer component which is
prevalent in all of these studies. This is still derived
from serum and contains a large amount of bovine
serumalbuminandotherproteins.Workisongoing
in our group, for example, to simplify these culture
conditions with components found in serum.
Quality control of hESC
A recent signiﬁcant concern has been the obser-
vation of karyotypic abnormalities such as trisomy
(3 chromosomes) and aneuploidy occurring during
long-term maintenance of hESC. Two groups have
suggested that mechanical cutting of colonies for
passaging may be a more stable method of prop-
agation (Buzzard et al. 2004; Mitalipova et al.
2005) than the use of enzymes for long-term
maintenance of hESC (Draper et al. 2004b). It has
been speculated however, that abnormal karyo-
types are unlikely to survive in long-term culture
unless there is a proliferative advantage (Peter
Andrews, University of Sheﬃeld, personal com-
munication). In contrast, a prolonged study of
several cell lines was not able to show any signiﬁ-
cant instabilities in long-term culture (Rosler et al.
2004). Furthermore, it is quite possible that short-
term passaging with enzymes (< 15 passages) will
not prejudice the normal karyotype (Mitalipova
et al. 2005). Nevertheless, karyotypic analysis will
have to be routinely conducted in expanded
hESC to prevent aneuploidy, which is associated
with carcinogenesis. Interestingly, few other stem
cell reports employ karyotyping as a standard,
although a recent publication on mesenchymal
stem cells shows that abnormal karyotypes can be
detected if the cells are passaged for 4–5 months
(Rubio et al. 2005). This is a far shorter period
than hESC cultures which have been propagated
for 2 years in a stable manner in our lab (unpub-
lished data). Another concern is the presence of
murine viruses such as retroviruses and murine
leukaemia viruses (muLV) in some of the feeder
layers that have been used in culture. However, a
new report has shown no evidence for infection of
hESC by feeder-derived muLV even after pro-
longed culture (Amit et al. 2005). But it has been
demonstrated that if muLV is present, hESC can
become infected, supporting the need for ongoing
screening. Other contaminants such as prion
proteins, host protein from cell lysates, cytokines
and DNA will also need to be tested for rou-
tinely. Historically, epigenetic instability in mouse
embryos, as exempliﬁed by poor development,
occurs if both the maternal or paternal genes are
expressed. Thus a concern has been raised that
genes that are not imprinted properly in hESC
may lead to retarded tissue development. A key-
note paper has just been published showing that
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and KCNQ1, are characteristically paternally
expressed, while three others which are typi-
cally maternally expressed are also monoallelically
expressed in several hESC lines (Rugg-Gunn et al.
2005). Thus it appears that epigenetic stability is
the norm in hESC, which seems to give the ﬁeld
a ‘green light’ to move forward with diﬀerentia-
tion studies. A ﬁnal concern is the potential of
hESC in generating an immune response in
transplanted mice. Again in 2004 (Li et al. 2004), it
was reported that these cells have the surprising
property of relative ‘immune privilege’. Both
undiﬀerentiated and diﬀerentiated hESC failed to
stimulate proliferation of alloreactive primary
human T cells, and in fact inhibited T-cell prolif-
eration, giving hope that transplanted hESC
derivatives may avoid rejection. One unexpected
discovery was the report of hESC being capable of
taking up substantial amounts of the potentially
immunogenic non-human sialic acid, Neu5Gc from
animal-derived serum replacements and mouse
feeders (Martin et al. 2005). Exposure of these
hESC to human sera containing antibodies speciﬁc
to Neu5Gc sialic acid resulted in binding of IgG,
deposition of complement and cell killing. This
reinforces the need to develop scaleable methods
of hESC expansion in completely animal source-
free, deﬁned culture media.
Methods for expansion and scale up
As hESC have a high capacity for self-renewal, it is
anticipated that the production of therapeutic
quantities of diﬀerentiated cells will exploit this
quality to enable the scale up of suﬃcient hESC
(the ‘starting material’), which would then be dif-
ferentiated into progenitors or the ﬁnal diﬀerenti-
ated phenotype. As progenitors have much
reduced replicative potential, expanding hESC
numbers ﬁrst is also a more eﬃcient approach to
scale up cells for regenerative therapies. Further-
more, existing methods yield diﬀerentiated prog-
eny at very low eﬃciencies (vide infra). Both
mESC and hESC are anchorage-dependent, and
grow uniquely as colonies, so that current methods
to scale them up have focused on the use of ﬂat
surfaces or matrices (Li et al. 2003; Berrill et al.
2005; Fong et al. 2005). It has been demonstrated
that mESC grow signiﬁcantly better on a surface
called petriperm (Oh et al. 2005), which triggered
an expansion up to 64-fold, compared to 9-fold in
Petri dishes over 6 days. Others have also achieved
high density cultures in matrices, although the
challenge here will be to expand hESC to high
densities in porous matrices and yet still be able to
harvest them easily for diﬀerentiation (Li et al.
2003). Once ESC have been produced to signiﬁ-
cant quantities, they are typically diﬀerentiated as
embryoid bodies consisting of a variety of cell
types. These structures have been cultivated in
both conventional stirred cultures with mESC and
hESC encapsulated in gels (Dang et al. 2004), and
human EBs have been grown in a rotating biore-
actor (Gerecht-Nir et al. 2004a). In both cases
these are very preliminary studies on a small scale;
it will be interesting to see if these methods can
produce suﬃciently pure populations of diﬀeren-
tiated cells for animal models and eventual clinical
studies.
It would also be much more convenient to scale
up hESC in suspension culture; however our own
attempts to grow them attached on microcarriers
or within alginate beads have been unsuccessful
(see Figure 2a, b). As the hESC inoculum consists
of relatively large clusters of 50 cells or more, they
are about the size of commercially available
microcarriers (about 150–200 lm in diameter):
thus, in our experience, it is not an easy task to
attach hESC clusters to microcarriers. Immobi-
lized hESC, when released from alginate beads
after 1 week of growth, were also of low viability.
We have further attempted to grow hESC in sus-
pension in the presence of polymers to protect the
cells from the eﬀects of shear during agitation in
0.5% Dextran 8000, 0.5% PEG 200, 0.5% PEI
2000, or 0.5% Pluronic; but in all cases, upon
gentle agitation, cells died or did not proliferate
signiﬁcantly (see Figure 2c–f, respectively). All
these conditions were unsuitable compared to
control cultures on feeders or in feeder-free con-
ditions on tissue culture plastic (Figure 2g, h).
Mouse ESC have been successfully grown in
suspension as aggregates; but, these cells are more
robust and behave quite diﬀerently than hESC,
which are more fragile and sensitive (unpublished
data). Thus alternative strategies of suspension
cultures might be attempted such as the use of
large pore macroporous beads to facilitate seeding
of large hESC clusters, or immobilized cultures
coated with matrigel to increase viability.
185Figure 2. Attempts at growing hESC in suspension (a) attached to feeders on Cytodex 3 microcarriers (b) immobilized in alginate (c) in
0.5% Dextran 8000 (d) in 0.5% PEG 200 (e) in 0.5% PEI 2000 (f) in 0.5% Pluronic respectively, were unsuccessful. (g) and (h) shows
control cultures of hESC grown on feeders and feeder free conditions. All pictures were taken at a magniﬁcation of 40· except for (a)
which was taken at 200·.
186Diﬀerentiation protocols
Since their isolation, a large number of groups
have shown the ability to diﬀerentiate hESC
to a variety of lineages with varying levels of
competency both in vivo and in vitro (Blum and
Benvenisty 2005). These include, for example,
neurons and glia which appear to be the default
pathway for hESC diﬀerentiation (Reubinoﬀ et al.
2001; Hornstein and Benvenisty 2004), while
cardiomyocytes (Mummery et al. 2003; Passier
et al. 2005), endothelial cells (Levenberg et al.
2002), blood cells (Murdoch et al. 2002), hepato-
cyte-like cells (Rambhatla et al. 2003) and insulin-
producing clusters (Segev et al. 2004) have also
been created. However, there is little or no data on
the eﬃciencies of methods or a comparison of
them, albeit anecdotal accounts suggest that the
eﬃciencies are very low (in the order of single digit
percentages). Taking the example of neural dif-
ferentiation for potential application in Parkin-
son’s Disease, one report has shown that PA6
stromal cells (Zeng et al. 2004) can generate
dopaminergic neural cells, while another group has
achieved this same lineage via the formation of
neurospheres in serum-free culture (Schulz et al.
2004). In both cases, the time of diﬀerentiation was
in the order of several weeks; however it is unclear
if a feeder layer was more eﬃcient than the serum-
free approach, though obviously the latter has
signiﬁcant clinical advantages.
Are diﬀerentiated cells also scaleable?
While there have been preliminary reports of
scaleable methods for diﬀerentiating hESC, there
have been a few studies for diﬀerentiating mESC
in bioreactors by the Zandstra group. For exam-
ple, a comparison of three methods for producing
embryoid bodies and cells of the haematopoietic
lineage from mESC identiﬁed encapsulated gels as
the preferred method (Dang et al. 2002) and a
study of controlled hypoxic conditions yielded 3.7
times more cardiomyocytes than normoxic
conditions (Bauwens et al. 2005). Others have
demonstrated that human EBs can be scaled up in
suspension, such as in small rotating bioreactors
(Gerecht-Nir et al. 2004a), and tried to encourage
diﬀerentiation on scaﬀolds (Gerecht-Nir et al.
2004b). However, these are early studies and more
innovative and scaleable methods of diﬀerentia-
tion and eﬃcient harvest of the cells for animal
studies clearly need to be explored.
Due to the vast possibilities of hESC, it is
envisaged that the types of manufacturing pro-
cesses to produce a particular lineage will be as
varied and complex as the property of the target
tissue. Exploiting the expansion capabilities of
hESC, we envisage that a common theme will be
the need to expand a large starting population of
hESC as source material. After which the initia-
tion of diﬀerentiation would occur through the
formation of either human embryoid bodies
(hEBs) or neurospheres in suspension cultures. An
initial puriﬁcation step to harvest the early pro-
genitor population and to remove residual hESC
will be required. At the next stage, some progeni-
tor cells, for example the islet or cardiomyocyte
clusters, which grow in suspension, could be
expanded in suspension; whilst the neuronal pro-
genitors would be grown on surfaces. A second
stage of puriﬁcation of progenitors will be required
to remove contaminating cell types ensuring a
relatively pure population of cells devoid of other
lineages, This would be followed by further
expansion of the ﬁnal phenotype such as pancre-
atic islets either in suspension, or cardiomyocytes
and dopaminergic neurons on surfaces with a
separate cocktail of growth factors or feeder cells.
A ﬁnal puriﬁcation step may be required where
ideally one would want to have only the functional
cell type. A schematic of possible processes for
three diﬀerent cell types is shown in Figure 3.
Conclusions
HESC have several well-characterized markers
for their recognition that have been used by
many laboratories; progress is also being made in
identifying deﬁned conditions for their expansion,
free of feeders, without serum replacer. Human
ESC culture will require unique quality control
assays such as karyotyping, immunogenicity tests,
elimination of residual hESC cells as well as the
routine assays for detecting contaminants, like
viruses, prions, host cell proteins, cytokines and
DNA. Expansion of hESC is as yet conﬁned to
surfaces, and although some progress is being
made in achieving higher cell densities, attempts
at suspension culture have been unsuccessful.
187Diﬀerentiation protocols are available for a host
of cell types, but optimization and better methods
of scale up will need to be developed to generate
suﬃcient cells for animal studies, as these are
currently in their infancy.
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